+

WO2003043992A1 - 4-oxoquinoline derivatives - Google Patents

4-oxoquinoline derivatives Download PDF

Info

Publication number
WO2003043992A1
WO2003043992A1 PCT/JP2002/012077 JP0212077W WO03043992A1 WO 2003043992 A1 WO2003043992 A1 WO 2003043992A1 JP 0212077 W JP0212077 W JP 0212077W WO 03043992 A1 WO03043992 A1 WO 03043992A1
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
aryl
hydrogen
oxoquinoline
oxoquinoline derivatives
Prior art date
Application number
PCT/JP2002/012077
Other languages
French (fr)
Japanese (ja)
Inventor
Hitoshi Kurata
Tohru Hasegawa
Takuya Ikeda
Keita Kono
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Priority to AU2002349676A priority Critical patent/AU2002349676A1/en
Publication of WO2003043992A1 publication Critical patent/WO2003043992A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

4-Oxoquinoline derivatives represented by the general formula (I), pharmacologically acceptable salts of the derivatives, and esters or other derivatives thereof, which exhibit excellent ileal bile acid transporter inhibiting activity: (I) wherein R1 is aryl or the like; R2 is lower alkyl or the like; R3 is -A-D-E-Gn+ (X-)n (wherein A is oxygen or the like; D is C1-12 alkylene or the like; E is a single bond or the like; Gn+ is substituted ammonio or the like; X- is an anion; and n is an integer of 1 or 2); R4, R6 and R7 are each hydrogen or the like; R5 is hydrogen or the like; and Ar is aryl or the like.
PCT/JP2002/012077 2001-11-19 2002-11-19 4-oxoquinoline derivatives WO2003043992A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002349676A AU2002349676A1 (en) 2001-11-19 2002-11-19 4-oxoquinoline derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001353064 2001-11-19
JP2001-353064 2001-11-19

Publications (1)

Publication Number Publication Date
WO2003043992A1 true WO2003043992A1 (en) 2003-05-30

Family

ID=19165142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/012077 WO2003043992A1 (en) 2001-11-19 2002-11-19 4-oxoquinoline derivatives

Country Status (3)

Country Link
AU (1) AU2002349676A1 (en)
TW (1) TW200300349A (en)
WO (1) WO2003043992A1 (en)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007102499A1 (en) * 2006-03-06 2007-09-13 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
US8232401B2 (en) 2002-11-20 2012-07-31 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
US8383819B2 (en) 2006-03-06 2013-02-26 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
US8759525B2 (en) 2007-09-11 2014-06-24 Gilhead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US8796459B2 (en) 2006-09-12 2014-08-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US8877931B2 (en) 2012-08-03 2014-11-04 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US20150031722A1 (en) * 2004-06-24 2015-01-29 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US10106528B2 (en) 2016-03-24 2018-10-23 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10392347B2 (en) 2015-10-14 2019-08-27 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as APJ agonists
US10493096B2 (en) 2016-02-09 2019-12-03 Albireo Ab Oral cholestyramine formulation and use thereof
US10610543B2 (en) 2016-02-09 2020-04-07 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10709755B2 (en) 2014-06-25 2020-07-14 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10881685B2 (en) 2017-08-09 2021-01-05 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10975046B2 (en) 2018-06-20 2021-04-13 Albireo Ab Crystal modifications of odevixibat
US10981952B2 (en) 2010-11-04 2021-04-20 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US11111224B2 (en) 2019-12-04 2021-09-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11180465B2 (en) 2019-12-04 2021-11-23 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11225466B2 (en) 2019-12-04 2022-01-18 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US11267794B2 (en) 2019-12-04 2022-03-08 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11306064B2 (en) 2018-06-05 2022-04-19 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11377429B2 (en) 2020-08-03 2022-07-05 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11572350B1 (en) 2020-12-04 2023-02-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11583539B2 (en) 2020-11-12 2023-02-21 Albireo Ab Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
US12187690B2 (en) 2019-02-06 2025-01-07 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10130241A (en) * 1996-10-31 1998-05-19 Wakunaga Pharmaceut Co Ltd New pyridonecarboxylic acid derivative or its salt and medicine comprising the same
WO2001034570A1 (en) * 1999-11-08 2001-05-17 Sankyo Company, Limited Nitrogenous heterocycle derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10130241A (en) * 1996-10-31 1998-05-19 Wakunaga Pharmaceut Co Ltd New pyridonecarboxylic acid derivative or its salt and medicine comprising the same
WO2001034570A1 (en) * 1999-11-08 2001-05-17 Sankyo Company, Limited Nitrogenous heterocycle derivatives

Cited By (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232401B2 (en) 2002-11-20 2012-07-31 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20150031722A1 (en) * 2004-06-24 2015-01-29 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US9931334B2 (en) 2005-12-28 2018-04-03 Vertex Pharmaceuticals Incorporated Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US10537565B2 (en) 2005-12-28 2020-01-21 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US11291662B2 (en) 2005-12-28 2022-04-05 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN101437801B (en) * 2006-03-06 2013-02-06 日本烟草产业株式会社 Process for preparing 4-oxoquinoline compounds
US8383819B2 (en) 2006-03-06 2013-02-26 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
US8420821B2 (en) 2006-03-06 2013-04-16 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
WO2007102499A1 (en) * 2006-03-06 2007-09-13 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
US8796459B2 (en) 2006-09-12 2014-08-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US8759525B2 (en) 2007-09-11 2014-06-24 Gilhead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11564916B2 (en) 2008-08-13 2023-01-31 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US12187812B2 (en) 2010-11-04 2025-01-07 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US10981952B2 (en) 2010-11-04 2021-04-20 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US11261212B2 (en) 2010-11-04 2022-03-01 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US11732006B2 (en) 2010-11-04 2023-08-22 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11147770B2 (en) 2012-02-27 2021-10-19 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US12214083B2 (en) 2012-02-27 2025-02-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11752106B2 (en) 2012-02-27 2023-09-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8877931B2 (en) 2012-08-03 2014-11-04 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US10709755B2 (en) 2014-06-25 2020-07-14 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
US11844822B2 (en) 2014-06-25 2023-12-19 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US10392347B2 (en) 2015-10-14 2019-08-27 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as APJ agonists
US10864228B2 (en) 2016-02-09 2020-12-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10758563B2 (en) 2016-02-09 2020-09-01 Albireo Ab Oral cholestyramine formulation and use thereof
US10610543B2 (en) 2016-02-09 2020-04-07 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10493096B2 (en) 2016-02-09 2019-12-03 Albireo Ab Oral cholestyramine formulation and use thereof
US10590113B2 (en) 2016-03-24 2020-03-17 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
US10106528B2 (en) 2016-03-24 2018-10-23 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
US10881685B2 (en) 2017-08-09 2021-01-05 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11306064B2 (en) 2018-06-05 2022-04-19 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10975046B2 (en) 2018-06-20 2021-04-13 Albireo Ab Crystal modifications of odevixibat
US11365182B2 (en) 2018-06-20 2022-06-21 Albireo Ab Crystal modifications of odevixibat
US12091394B2 (en) 2018-06-20 2024-09-17 Albireo Ab Crystal modifications of odevixibat
US11802115B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US12187690B2 (en) 2019-02-06 2025-01-07 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US11603359B2 (en) 2019-02-06 2023-03-14 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US11773071B2 (en) 2019-02-06 2023-10-03 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US11111224B2 (en) 2019-12-04 2021-09-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11708340B2 (en) 2019-12-04 2023-07-25 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11225466B2 (en) 2019-12-04 2022-01-18 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US12202809B2 (en) 2019-12-04 2025-01-21 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11891368B2 (en) 2019-12-04 2024-02-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US12024495B2 (en) 2019-12-04 2024-07-02 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US12060338B2 (en) 2019-12-04 2024-08-13 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11267794B2 (en) 2019-12-04 2022-03-08 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11180465B2 (en) 2019-12-04 2021-11-23 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11377429B2 (en) 2020-08-03 2022-07-05 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11583539B2 (en) 2020-11-12 2023-02-21 Albireo Ab Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors
US11572350B1 (en) 2020-12-04 2023-02-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US12134606B2 (en) 2020-12-04 2024-11-05 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof

Also Published As

Publication number Publication date
TW200300349A (en) 2003-06-01
AU2002349676A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
WO2003043992A1 (en) 4-oxoquinoline derivatives
EP1026149A4 (en) Amidocarboxylic acid derivatives
CA2200316A1 (en) Imidazole derivative
EP0758653A4 (en) Imidazoquinazoline derivatives
CA2325741A1 (en) Urea derivatives having tnf- .alpha. production inhibitory effects
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
DK0870765T3 (en) Aminothiazole derivative, drug containing the same and intermediate for the preparation of the compound
NO20031490D0 (en) Aliphatic nitrogen-containing 5-edged ring compound
HU9602466D0 (en) Naphthalene derivatives as prostaglandin i2 agonits
EP0669324A4 (en) Quinazoline compound.
TW200606137A (en) Urea derivatives
WO2003059880A1 (en) Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
TW200744659A (en) Preparation for preventing and ameliorating wrinkle
UA66864C2 (en) Urea derivatives, a pharmaceutical composition and methods of treating or preventing inflammatory, autoimmune or respiratory diseases
AU2629795A (en) Aniline derivative having the effect of inhibiting nitrogen monoxide synthase
PL351878A1 (en) Amino compound derivatives
DE69612835D1 (en) TRICYCLIC CONNECTIONS
CA2101310A1 (en) Novel arylglycinamide derivatives and preparative processes therefor
EP1241158A4 (en) Compound having hydroxycarbonyl-halogenoalkyl side chain
DK1362844T3 (en) Benzylamine analog
CA2209422A1 (en) 4-amino-3-acylnaphthyridine derivatives
AU9025601A (en) Cephem compounds and esbl-detecting reagents containing the same
EP0680960A4 (en) IMIDAZOLE CONNECTION.
EP0702014A4 (en) Dc-89 derivative
DE69224613D1 (en) Peptides, production and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载